Arcus Biosciences Inc (NYSE: RCUS) kicked off on Tuesday, down -2.83% from the previous trading day, before settling in for the closing price of $25.8. Over the past 52 weeks, RCUS has traded in a range of $6.50-$26.40.
During the last 5-year period, the sales drop of Healthcare Sector giant was -10.20%. While this was happening, its average annual earnings per share was recorded -15.74%. With a float of $74.91 million, this company’s outstanding shares have now reached $107.10 million.
Arcus Biosciences Inc (RCUS) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Arcus Biosciences Inc is 39.46%, while institutional ownership is 53.16%. The most recent insider transaction that took place on Dec 04 ’25, was worth 2,050,599. In this transaction President of this company sold 82,997 shares at a rate of $24.71, taking the stock ownership to the 954,063 shares. Before that another transaction happened on Dec 04 ’25, when Company’s Officer proposed sale 82,997 for $25.26, making the entire transaction worth $2,096,504.
Arcus Biosciences Inc (RCUS) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -1.03 earnings per share (EPS), higher than consensus estimate (set at -1.2) by 0.17. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.05 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -15.74% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.89% during the next five years compared to -10.20% drop over the previous five years of trading.
Arcus Biosciences Inc (NYSE: RCUS) Trading Performance Indicators
Take a look at Arcus Biosciences Inc’s (RCUS) current performance indicators. Last quarter, stock had a quick ratio of 3.65. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.43, a number that is poised to hit -1.14 in the next quarter and is forecasted to reach -4.12 in one year’s time.
Technical Analysis of Arcus Biosciences Inc (RCUS)
Looking closely at Arcus Biosciences Inc (NYSE: RCUS), its last 5-days average volume was 1.63 million, which is a jump from its year-to-date volume of 1.15 million. As of the previous 9 days, the stock’s Stochastic %D was 68.85%.
During the past 100 days, Arcus Biosciences Inc’s (RCUS) raw stochastic average was set at 92.43%, which indicates a significant increase from 78.79% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.32 in the past 14 days, which was higher than the 0.87 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.49, while its 200-day Moving Average is $11.95. However, in the short run, Arcus Biosciences Inc’s stock first resistance to watch stands at $25.98. Second resistance stands at $26.89. The third major resistance level sits at $27.37. If the price goes on to break the first support level at $24.58, it is likely to go to the next support level at $24.10. Now, if the price goes above the second support level, the third support stands at $23.19.
Arcus Biosciences Inc (NYSE: RCUS) Key Stats
The company with the Market Capitalisation of 3.10 billion has total of 107,974K Shares Outstanding. Its annual sales at the moment are 258,000 K in contrast with the sum of -283,000 K annual income. Company’s last quarter sales were recorded 26,000 K and last quarter income was -135,000 K.
